Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
Dr. Edward Garon, David Geffen School of Medicine at UCLA, describes the exciting developments with LDK-378 and potentially other second generation ALK inhibitors for crizotinib-resistant ALK-positive advanced NSCLC.
leggi di più
leggi meno
10 anni fa
#2013, #asco, #cancergrace, #david, #dr, #edward, #ercc1, #garon, #geffen, #grace, #gracecast, #madeit, #medicine, #of, #rrm1, #school, #ucla
